An updated resource has been released to guide healthcare professionals on the best ways to care for people with MS in Australia and New Zealand.
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider ublituximab (Briumvi®) for treating relapsing remitting MS at their May 2025 meeting.
As we step into an uncertain 2025, CEO Rohan Greenland highlights seven key initiatives set to bring optimism to the MS Community.
As co-authors of a new scientific paper, people with MS spoke about their experiences of direct involvement in medical research.
Researchers and people living with MS have shortlisted antiviral medications targeting EBV for clinical trials in MS.
Researchers have found that higher levels of omega-6 polyunsaturated fatty acids in the blood are linked to a lower risk of developing MS.
In 2015, 21-year-old Cass David was working in a Melbourne dental clinic and considering a career in nursing. But then, she began to feel unwell. Â “The maxillofacial surgeon I worked with at the clinic told me to get an MRI. I did, and soon found out I had MS.”
As we take our first steps into 2025, let’s take a moment to look back at ten of the biggest MS Australia news stories from 2024.
In a groundbreaking development, the PBAC has recommended listing ravulizumab (Ultomiris®) on the PBS for adults with NMOSD, marking a revolutionary step forward in NMOSD care.
